Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman. Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690

Reference

Title
Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman
Volume & Issue
Volume 31, Issue 4
Pages
683-690

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • “If you had been diagnosed with chronic myeloid leukemia (CML) in 1999, chances were that you would not be alive today. Just 3 out of 10 patients survived for…  
  • Approximately one third of men diagnosed with prostate cancer will opt for surgical treatment.  
  • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…  
  • The 5-year survival rate for localized breast cancer, is 98%–an 18% increase since the 1950s.